SS-31 (30mg Vial) Dosage Protocol

SS-31 (30 mg Vial) Dosage Protocol

Quickstart Highlights

SS‑31 (elamipretide) is a mitochondria‑targeted tetrapeptide that selectively binds cardiolipin in the inner mitochondrial membrane[1], stabilizing electron transport chain complexes and reducing reactive oxygen species production while enhancing ATP synthesis[2]. This peptide has demonstrated protective effects in preclinical models of heart failure, neurodegenerative disease, and age‑related muscle atrophy, and received FDA accelerated approval in 2025 as the first treatment for Barth syndrome[3]. This educational protocol presents a once‑daily subcutaneous approach using the 30 mg vial format with practical reconstitution for insulin‑syringe measurements.

  • Reconstitute: Add 3.0 mL bacteriostatic water → ~10 mg/mL concentration for convenient dosing.
  • Typical daily range: 5–10 mg once daily (gradual titration); advanced protocols may reach 15–20 mg/day under supervision.
  • Easy measuring: At 10 mg/mL, 1 unit = 0.01 mL = 100 mcg on a U‑100 insulin syringe.
  • Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); use within 4 weeks.
    • SS-31 30mg Vial

    Dosing & Reconstitution Guide

    Educational guide for reconstitution and daily dosing

    Standard / Gradual Approach (3.0 mL = ~10 mg/mL)

    Week Daily Dose Units (per injection) (mL)
    Weeks 1–2 5 mg (5000 mcg) 50 units (0.50 mL)
    Weeks 3–8 10 mg (10,000 mcg) 100 units (1.0 mL)

    Frequency: Inject once daily subcutaneously at a consistent time. This 30 mg vial reconstituted with 3.0 mL keeps standard doses within a single insulin syringe for convenience and accuracy.

    Reconstitution Steps

  • Draw 3.0 mL bacteriostatic water with a sterile syringe.
  • Inject slowly down the vial wall; avoid vigorous shaking to prevent foaming.
  • Gently swirl/roll until fully dissolved (clear solution).
  • Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; use within 4 weeks.

    • Advanced / Aggressive Approach (3.0 mL = ~10 mg/mL)

    Week Daily Dose Units (per injection) (mL)
    Weeks 1–2 5 mg (5000 mcg) 50 units (0.50 mL)
    Weeks 3–4 10 mg (10,000 mcg) 100 units (1.0 mL)
    Weeks 5–8 15 mg (15,000 mcg) Split: 2 × 75 units (0.75 mL each)
    Optional Weeks 9–12 20 mg (20,000 mcg) Split: 2 × 100 units (1.0 mL each)

    Note: Advanced dosing (15–20 mg/day) is based on short‑term clinical trial protocols[4][5] for severe mitochondrial conditions and should only be pursued under medical supervision. Doses above 10 mg require splitting into two separate subcutaneous injections at different sites. Clinical trials have not extensively evaluated SS‑31 beyond 12 weeks; extended use requires careful monitoring.

    Important: This guide is for educational purposes only and is not medical advice.

    Supplies Needed

    Plan based on an 8–12 week daily protocol with gradual titration using 30 mg vials.

  • Peptide Vials (SS‑31, 30 mg each):

    • 8 weeks (Standard: 5–10 mg/day) ≈ 17 vials
    • 12 weeks (Standard maintenance at 10 mg/day) ≈ 26 vials
    • 12 weeks (Advanced: escalating to 15 mg/day) ≈ 35 vials
  • Insulin Syringes (U‑100, 1 mL capacity):

    • Per week (standard dosing): 7 syringes (1/day)
    • 8 weeks: 56 syringes
    • 12 weeks: 84 syringes
    • Advanced protocols with split injections may require 2 syringes per day for higher doses
  • Bacteriostatic Water (30 mL bottles): Use 3.0 mL per vial for reconstitution.

    • 8 weeks (17 vials): 51 mL → 2 × 30 mL bottles
    • 12 weeks (26 vials): 78 mL → 3 × 30 mL bottles
    • 12 weeks (35 vials, advanced): 105 mL → 4 × 30 mL bottles
  • Alcohol Swabs: One for the vial stopper + one for the injection site each day.

    • Per week: 14 swabs (2/day)
    • 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
    • 12 weeks: 168 swabs → recommend 2 × 100‑count boxes
    • SS-31 30mg Vial

    View Supplier

    Insulin Syringes

    View Supplier

    Bacteriostatic Water

    View Supplier

    Alcohol Pads

    View Supplier

    Protocol Overview

    Concise summary of the once‑daily subcutaneous regimen.

  • Goal: Support mitochondrial function, enhance ATP production, and reduce oxidative stress in tissues with high metabolic demand[1][2].
  • Schedule: Daily subcutaneous injections for 8–12 weeks (clinical trials typically 4–12 weeks).
  • Dose Range: 5–10 mg daily (standard); 15–20 mg daily (advanced, under supervision).
  • Reconstitution: 3.0 mL per 30 mg vial (~10 mg/mL) for convenient single‑syringe administration.
  • Storage: Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F); use within 4 weeks.